乐天堂app下载

After leaving Clare College in Cambridge, Dr Christopher Swain initially followed an academic path, gaining a PhD and undertaking postdoctoral research at 乐天堂app下载 University of Southampton, where he had an initial foray into lecturing.

In 1986, Christopher was invited to join 乐天堂app下载 Neuroscience Research Centre (NRC) created by Merck in Harlow and spent nearly 20 years 乐天堂app下载re, rising to Senior Director responsible for MedChem and computational chemistry groups. He was Chemistry Director of 乐天堂app下载 project team that discovered and developed 乐天堂app下载 NK1 antagonist Emend, and this work was recognised by 乐天堂app下载 BMCS prize.

In 2006, 乐天堂app下载 NRC was closed, and Christopher founded Cambridge MedChem Consulting. This has led to opportunities to work with a number of brilliant scientists around 乐天堂app下载 world, providing medicinal chemistry and computational chemistry support to small and large Pharma companies, academic groups and start-ups. Christopher is also on 乐天堂app下载 SAB of several organisations. He continues to support 乐天堂app下载 teaching of drug discovery in Medchem summer schools and helps to develop university courses on computational-driven drug discovery.

Christopher is an active member of 乐天堂app下载 Royal Society of Chemistry, as Chair of 乐天堂app下载 Chemical Information and Computer Applications Group and a committee member of 乐天堂app下载 Biological and Medicinal Chemistry Sector. He has organised over 30 RSC conferences on AI in chemistry, open source chemistry, macrocycles, protein structure prediction, and 乐天堂app下载 Cambridge MedChem Meeting. He has also organised twenty open source workshops for chemists, and is an active member of 乐天堂app下载 Cambridge Cheminformatics network. He has over 100 publications.